The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
Kongsberg Gruppen after earnings: The company catches up with the sector
Market wrap: European indices attempt a rebound after Wall Street’s record selloff 🔨
Morning wrap: Tech sector sell-off (06.02.2026)
Amazon shares tumble 10% as investors recoil at the price of AI dominance